Rody A, Karn T, Gätje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhäberle E, Holtrich U, von Minckwitz G, Kaufmann M
Department of Obstetrics and Gynecology, J.W. Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
Breast. 2007 Feb;16(1):86-93. doi: 10.1016/j.breast.2006.06.008. Epub 2006 Sep 28.
Gene expression analysis in breast cancer patients undergoing neoadjuvant chemotherapy is an interesting tool for identification of gene signatures and new markers to predict tumor response. However, the detection of predictive markers strongly depends on the drugs used in the specific therapeutic setting. There is growing evidence that topoisomerase II-alpha (TOPO IIalpha) is a marker for anthracycline-, and microtubule-associated protein tau (MAPT) for taxane sensitivity. HER-2 has been described as a marker of both anthracycline and taxane sensitivity. We performed gene expression profiling of 50 patients within the GEPARTRIO study, an anthracycline and taxane neoadjuvant chemotherapy trial. Here we investigate the predictive value of TOPO IIalpha, MAPT and HER-2 mRNA expression for pathological complete response (pCR) in this setting. Interestingly, HER-2 gene expression was strongly predictive of pCR (P=0.017) as well as overall response (P=0.037) and clinical complete response (cCR, P=0.050). In contrast, for both TOPO IIalpha and MAPT no correlation with pCR was observed in our sample group.
对接受新辅助化疗的乳腺癌患者进行基因表达分析，是识别基因特征和预测肿瘤反应的新标志物的一项有趣工具。然而，预测性标志物的检测很大程度上取决于特定治疗方案中所使用的药物。越来越多的证据表明，拓扑异构酶II-α（TOPO IIα）是蒽环类药物敏感性的标志物，而微管相关蛋白tau（MAPT）是紫杉烷敏感性的标志物。HER-2已被描述为蒽环类药物和紫杉烷敏感性的标志物。我们在GEPARTRIO研究（一项蒽环类药物和紫杉烷新辅助化疗试验）中对50例患者进行了基因表达谱分析。在此，我们研究了在这种情况下TOPO IIα、MAPT和HER-2 mRNA表达对病理完全缓解（pCR）的预测价值。有趣的是，HER-2基因表达对pCR（P=0.017）、总体反应（P=0.037）和临床完全缓解（cCR，P=0.050）具有很强的预测性。相比之下，在我们的样本组中未观察到TOPO IIα和MAPT与pCR之间存在相关性。
